Catalog No.
DVV03111
Expression system
Mammalian Cells
Species reactivity
Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1)
Host species
Human
Isotype
IgG1-lambda
Clonality
Monoclonal
Target
Envelope glycoprotein gp160, Env polyprotein, Surface protein gp120, SU, Glycoprotein 120, gp120, Transmembrane protein gp41, TM, Glycoprotein 41, gp41, env
Concentration
1.44 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P04578
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
10E8#
HIV-1 envelopes from virions that persist in plasma on antiretroviral therapy show reduced susceptibility to autologous immunoglobulins and variable sensitivity to broadly neutralizing monoclonal antibodies., PMID:40502069
A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning., PMID:40383778
Conformational trajectory of the HIV-1 fusion peptide during CD4-induced envelope opening., PMID:40382314
Potent HIV-1 miniprotein inhibitors targeting highly conserved gp41 epitopes., PMID:40239787
Ab initio prediction of specific phospholipid complexes and membrane association of HIV-1 MPER antibodies by multi-scale simulations., PMID:40192122
The membrane-proximal external region of human immunodeficiency virus (HIV-1) envelope glycoprotein trimers in A18-lipid nanodiscs., PMID:40089599
Isolation and structure of broad SIV-neutralizing antibodies reveal a proximal helical MPER epitope recognized by a rhesus multi-donor class., PMID:39792559
Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles., PMID:39721354
A multidonor class of highly glycan-dependent HIV-1 gp120-gp41 interface-targeting broadly neutralizing antibodies., PMID:39675002
Vaccine-elicited and naturally elicited antibodies differ in their recognition of the HIV-1 fusion peptide., PMID:39611147
Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation., PMID:39508605
Stoichiometry of HIV-1 Envelope Glycoprotein Protomers with Changes That Stabilize or Destabilize the Pretriggered Conformation., PMID:39484577
Potent broadly neutralizing antibodies mediate efficient antibody-dependent phagocytosis of HIV-infected cells., PMID:39466835
Generation of a Nonbilayer Lipid Nanoenvironment after Epitope Binding Potentiates Neutralizing HIV-1 MPER Antibody., PMID:39446590
A New Chimeric Antibody against the HIV-1 Fusion Inhibitory Peptide MT-C34 with a High Affinity and Fc-Mediated Cellular Cytotoxicity., PMID:39336102
Conformational trajectory of the HIV-1 fusion peptide during CD4-induced envelope opening., PMID:39314380
Conjugation of anti-HIV gp41 monoclonal antibody to a drug capable of targeting resting lymphocytes produces an effective cytotoxic anti-HIV immunoconjugate., PMID:39283123
The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity., PMID:39248460
Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in the presence of CD4-mimetics., PMID:39230306
Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques., PMID:39213340
Alpaca-derived nanobody targeting the hydrophobic pocket of the HIV-1 gp41 NHR broadly neutralizes HIV-1 by blocking six-helix bundle formation., PMID:39176008
mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies., PMID:39119336
Impact of glycan depletion, glycan debranching and increased glycan charge on HIV-1 neutralization sensitivity and immunogenicity., PMID:39115361
The Performance of the Current Algorithm of HIV Diagnosis., PMID:39086412
Design of soluble HIV-1 envelope trimers free of covalent gp120-gp41 bonds with prevalent native-like conformation., PMID:39028623
Natural Variation in HIV-1 Entry Kinetics Map to Specific Residues and Reveal an Interdependence Between Attachment and Fusion., PMID:38979136
Membrane HIV-1 envelope glycoproteins stabilized more strongly in a pretriggered conformation than natural virus Envs., PMID:38979012
Applying Flow Virometry to Study the HIV Envelope Glycoprotein and Differences Across HIV Model Systems., PMID:38932227
The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity., PMID:38895270
Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in presence of CD4-mimetics., PMID:38883797
Vaccination induces broadly neutralizing antibody precursors to HIV gp41., PMID:38816615
Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates., PMID:38768344
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans., PMID:38761800
HIV-1 envelope facilitates the development of protease inhibitor resistance through acquiring mutations associated with viral entry and immune escape., PMID:38699474
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS., PMID:38587079
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy Individuals., PMID:38562833
Competitive assembly resolves the stoichiometry of essential proteins in infectious HIV-1 virions., PMID:38559103
Preservation of memory B cell homeostasis in an individual producing broadly neutralising antibodies against HIV-1., PMID:38370662
A two-step mechanism for the binding of the HIV-1 MPER epitope by the 10E8 antibody onto biosensor-supported lipid bilayers., PMID:38339834
Clinical, epidemiological, and drug resistance insights into HIV-positive patients in Meizhou, China., PMID:38314093
Stable expression of HIV-1 MPER extended epitope on the surface of the recombinant probiotic bacteria Escherichia Coli Nissle 1917 using CRISPR/Cas9., PMID:38311724
Molecular dynamics simulations show how antibodies may rescue HIV-1 mutants incapable of infecting host cells., PMID:38111161
Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility., PMID:37940661
Higher HIV-1 Env gp120-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity Is Associated with Lower Levels of Defective HIV-1 Provirus., PMID:37896832
Liposome-based peptide vaccines to elicit immune responses against the membrane active domains of the HIV-1 Env glycoprotein., PMID:37793559
Soluble CD4 and low molecular weight CD4-mimetic compounds sensitize cells to be killed by anti-HIV cytotoxic immunoconjugates., PMID:37772823
Comprehensive profiling of pre-infection antibodies identifies HIV targets associated with viremic control and viral load., PMID:37744365
Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein pretriggered conformation., PMID:37696048
Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells., PMID:37681958
Enhancement of Neutralization Responses through Sequential Immunization of Stable Env Trimers Based on Consensus Sequences from Select Time Points by Mimicking Natural Infection., PMID:37628824
For research use only. Not for human or drug use.
